Trial Profile
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jun 2019
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms REGAL
- Sponsors AstraZeneca
- 13 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 22 Nov 2016 This trial has been completed in France.
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.